Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| B cell | 16 studies | 21% ± 4% | |
| naive B cell | 16 studies | 25% ± 10% | |
| conventional dendritic cell | 11 studies | 27% ± 9% | |
| macrophage | 10 studies | 25% ± 6% | |
| memory B cell | 8 studies | 25% ± 8% | |
| dendritic cell | 7 studies | 27% ± 12% | |
| myeloid cell | 4 studies | 23% ± 4% | |
| mononuclear phagocyte | 3 studies | 26% ± 5% | |
| pro-B cell | 3 studies | 23% ± 4% | |
| plasmacytoid dendritic cell | 3 studies | 22% ± 2% |
Insufficient scRNA-seq data for expression of HLA-DOA at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 100% | 1183.75 | 89 / 89 | 88% | 56.26 | 790 / 901 |
| breast | 99% | 1090.18 | 455 / 459 | 86% | 29.51 | 963 / 1118 |
| lung | 100% | 2167.41 | 576 / 578 | 85% | 42.00 | 982 / 1155 |
| prostate | 98% | 886.97 | 241 / 245 | 77% | 15.74 | 385 / 502 |
| thymus | 94% | 807.45 | 613 / 653 | 76% | 34.22 | 461 / 605 |
| uterus | 94% | 707.52 | 159 / 170 | 63% | 23.72 | 290 / 459 |
| bladder | 86% | 483.90 | 18 / 21 | 57% | 20.85 | 286 / 504 |
| skin | 66% | 313.67 | 1195 / 1809 | 69% | 42.02 | 327 / 472 |
| intestine | 84% | 876.12 | 813 / 966 | 50% | 16.26 | 263 / 527 |
| ovary | 59% | 246.87 | 107 / 180 | 74% | 35.52 | 320 / 430 |
| pancreas | 38% | 142.24 | 125 / 328 | 86% | 33.02 | 153 / 178 |
| adrenal gland | 93% | 984.13 | 240 / 258 | 30% | 4.65 | 68 / 230 |
| esophagus | 83% | 373.45 | 1199 / 1445 | 38% | 9.55 | 70 / 183 |
| brain | 50% | 259.68 | 1308 / 2642 | 66% | 26.52 | 468 / 705 |
| stomach | 55% | 226.57 | 197 / 359 | 57% | 17.85 | 164 / 286 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 215.81 | 29 / 29 |
| spleen | 100% | 4696.70 | 241 / 241 | 0% | 0 | 0 / 0 |
| adipose | 97% | 976.94 | 1162 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 91% | 2835.30 | 845 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 85% | 637.42 | 1136 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 82% | 35.92 | 37 / 45 |
| liver | 31% | 85.22 | 70 / 226 | 33% | 7.80 | 132 / 406 |
| heart | 43% | 134.59 | 366 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 20% | 5.53 | 16 / 80 |
| muscle | 9% | 25.95 | 76 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0050870 | Biological process | positive regulation of T cell activation |
| GO_0050778 | Biological process | positive regulation of immune response |
| GO_0002587 | Biological process | negative regulation of antigen processing and presentation of peptide antigen via MHC class II |
| GO_0045580 | Biological process | regulation of T cell differentiation |
| GO_0002503 | Biological process | peptide antigen assembly with MHC class II protein complex |
| GO_0031902 | Cellular component | late endosome membrane |
| GO_0042613 | Cellular component | MHC class II protein complex |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005765 | Cellular component | lysosomal membrane |
| GO_0023026 | Molecular function | MHC class II protein complex binding |
| GO_0032395 | Molecular function | MHC class II receptor activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0042605 | Molecular function | peptide antigen binding |
| Gene name | HLA-DOA |
| Protein name | HLA class II histocompatibility antigen, DO alpha chain (MHC DN-alpha) (MHC DZ alpha) (MHC class II antigen DOA) MHC class II antigen HLA class II histocompatibility antigen, DO alpha chain Major histocompatibility complex, class II, DO alpha HLA-DOA |
| Synonyms | HLA-DNA HLA-DZA |
| Description | FUNCTION: Important modulator in the HLA class II restricted antigen presentation pathway by interaction with the HLA-DM molecule in B-cells. Modifies peptide exchange activity of HLA-DM. |
| Accessions | A0A1V0E3R6 A0A1V0E3Q6 ENST00000383225.2 A0A1V0E3R8 A0A1V0E3M7 F6WU08 ENST00000383226.4 A0A140T8X4 ENST00000452598.2 A0A1V0E3N6 A0A1V0E3Q8 ENST00000438987.2 A0A1V0E3T1 A0A140T9F9 ENST00000374813.1 A0A1V0E3P3 A0A1V0E3S6 A0A1V0E3P9 ENST00000426685.2 ENST00000229829.7 A0A140T9G3 A0A1V0E3M6 A0A1V0E3P1 P06340 ENST00000426070.2 A0A1V0E3Q2 A0A1V0E3P0 A0A1V0E3R0 A0A1V0E3P8 A0A1V0E3N7 ENST00000455325.1 A0A1V0E3R3 A0A1V0E3Q7 ENST00000416763.1 A0A1V0E3S7 A0A1V0E3Q3 X5CKB7 A0A140T9G1 A0A1V0E3S4 X5CF87 A0A1V0E3Q4 A0A140T9P4 A0A1V0E3S0 A0A1V0E3P6 A0A1V0E3N3 ENST00000457663.1 A0A140T9J7 A0A1V0E3R4 ENST00000444109.1 A0A1V0E3Q5 A0A1V0E3Q1 ENST00000434335.2 A0A1V0E3N1 ENST00000418857.1 |
